inactivated M. manresensis
Commercial- Indications
- Tuberculosis
Company intelligence / Profile preview
Manremyc
Catalonia, Spainlinkedin.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Commercial
01
Overview
Manremyc has developed Nyaditum resae®, a probiotic nutritional supplement that reduces the risk of developing tuberculosis. Clinical trials have proven it triggers an immune response that protects against tuberculosis bacteria with a two-week administration regimen[5].
- Therapeutic areas
- Infectious Diseases
- Modalities
- ProbioticNutritional supplement
- Industry
- Food & Nutrition
02
Drug pipeline
1 asset03
Partnerships
Reig JofreSRS Life Sciences GroupTablets India
Beyond the preview
Go deeper on Manremyc.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Manremyc.